**PUBLIC HEALTH SERVICE**

**BIOLOGICAL MATERIALS LICENSE AGREEMENT**

**INTERNAL USE ONLY**

This **Agreement** is based on the model Biological Materials Internal Use Agreement adopted by the U.S. Public Health Service (“**PHS**”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“**NIH**”), the Centers for Disease Control and Prevention (“**CDC**”), and the Food and Drug Administration (“**FDA**”), which are agencies of the **PHS** within the Department of Health and Human Services (“**HHS**”).

This Cover Page identifies the Parties to this **Agreement**:

The U.S. Department of Health and Human Services, as represented by

[Insert the full name of the IC]

an Institute or Center (hereinafter referred to as the “**IC**”) of the

[INSERT as appropriate: NIH, CDC, or FDA]

and

[Insert Company’s official name],

hereinafter referred to as the “**Licensee**”,

having offices at [Insert Company’s address],

created and operating under the laws of [Insert State of Incorporation].

**Tax ID No.:\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

1. Definitions:
   1. “**Government**” means the government of the United States of America.
   2. “**Materials**” means the following biological materials including all progeny, subclones, and unmodified derivatives thereof: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_, as described in \_\_\_\_\_\_\_\_\_\_\_ and developed in the laboratory of \_\_\_\_\_\_\_\_\_\_\_\_ at the **IC**.
   3. “**Licensed Products**” means \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_.
2. The **Licensee** desires to obtain a license from the **IC** to use the **Materials** provided under this **Agreement** in its commercial research or product development and marketing activities. The **Licensee** represents that it has the facilities, personnel, and expertise to use the **Materials** or the **Licensed Products** for commercial purposes and agrees to expend reasonable efforts and resources to develop the **Materials** or the **Licensed Products** for commercial use or commercial research.
3. The **IC** hereby grants to the **Licensee** a non-exclusive license, within its research facilities, to make, have made, use, but not to sell the **Materials** or the **Licensed Products**.
4. In consideration of the grant in Paragraph 3, the **Licensee** agrees to make the following payments to the **IC**:
   1. Within sixty (60) days of its execution of this **Agreement**, a noncreditable, nonrefundable license issue royalty of \_\_\_\_\_\_\_\_\_\_ dollars ($X);
   2. The first minimum annual royalty of \_\_\_\_\_\_\_\_\_\_ dollars ($XX) is due within sixty (60) days of the effective date of this **Agreement** and may be prorated according to the fraction of the calendar year remaining between the effective date of this **Agreement** and the next subsequent January 1;
   3. Subsequent minimum annual royalty payments are due and payable on January 1 of each calendar year; and
   4. All payments required under this **Agreement** shall be paid in U.S. dollars and payment options are listed in Appendix B. For conversion of foreign currency to U.S. dollars, the conversion rate shall be the New York foreign exchange rate quoted in *The Wall Street Journal* on the day that the payment is due.
      1. Any loss of exchange, value, taxes, or other expenses incurred in the transfer or conversion to U.S. dollars shall be paid entirely by the **Licensee**; and
      2. Additional royalties may be assessed by the **IC** on any payment that is more than ninety (90) days overdue at the rate of one percent (1%) per month. This one percent (1%) per month rate may be applied retroactively from the original due date until the date of receipt by the **IC** of the overdue payment and additional royalties. The payment of any additional royalties shall not prevent the **IC** from exercising any other rights it may have as a consequence of the lateness of any payment.
5. Upon receipt by the **IC** of the license issue royalty and the prorated first year annual royalty and verification of these royalties, the **IC** agrees to provide the **Licensee** with samples of the **Materials**, as available, and to replace these **Materials**, as available, at reasonable cost, in the event of their unintentional destruction. The **IC** shall provide the **Materials** to the **Licensee** at the **Licensee’s** expense and as specified in Appendix A.
6. This **Agreement** shall become effective on the date when the last party to sign has executed this **Agreement**, unless the provisions of Paragraph 23 are not fulfilled, and shall expire \_\_\_\_\_\_\_\_ (X) years from this effective date, unless previously terminated under the terms of Paragraphs 13 or 14.
7. The **Licensee** agrees to retain control over the **Materials** and the **Licensed Products**, and not to distribute them to third parties without the prior written consent of the **IC**.
8. This **Agreement** does not preclude the **IC** from distributing the **Materials** or the **Licensed Products** to third parties for research or commercial purposes.
9. By this **Agreement**, the **IC** grants no patent rights expressly or by implication to any anticipated or pending **IC** patent applications or issued patents.
10. NO WARRANTIES, EXPRESS OR IMPLIED, ARE OFFERED AS TO THE MERCHANTABILITY OR FITNESS FOR ANY PURPOSE OF THE **MATERIALS** PROVIDED TO THE **LICENSEE** UNDER THIS **AGREEMENT**, OR THAT THE **MATERIALS** OR THE **LICENSED PRODUCTS** MAY BE EXPLOITED WITHOUT INFRINGING THE PATENT RIGHTS OF ANY THIRD PARTIES. The **Licensee** accepts license rights to the **Materials** “as is”, and the **IC** does not offer any guarantee of any kind.
11. The **Licensee** agrees to indemnify and hold harmless the **Government** from any claims, costs, damages, or losses that may arise from or through the **Licensee’s** use of the **Materials** or the **Licensed Products**. The **Licensee** further agrees that it shall not by its action bring **Government** into any lawsuit involving the **Materials** or the **Licensed Products**.
12. The **Licensee** agrees in its use of the **Materials** or the **Licensed Products** to comply with all applicable statutes, regulations, and guidelines, including **NIH** and **HHS** regulations and guidelines. The **Licensee** agrees not to use the **Materials** or the **Licensed Products** for research involving human subjects or clinical trials in the United States without complying with [21 C.F.R. Part 50](http://www.access.gpo.gov/nara/cfr/waisidx_02/21cfr50_02.html) and [45 C.F.R. Part 46](http://www.access.gpo.gov/nara/cfr/waisidx_03/45cfr46_03.html). The **Licensee** agrees not to use the **Materials** or the **Licensed Products** for research involving human subjects or clinical trials outside of the United States without notifying the **IC**, in writing, of such research or trials and complying with the applicable regulations of the appropriate national control authorities. Written notification to the **IC** of research involving human subjects or clinical trials outside of the United States shall be given no later than sixty (60) days prior to commencement of such research or trials.
13. The **Licensee** may terminate this **Agreement** upon thirty (30) days written notice to the **IC** but only after sixty (60) days from the effective date of this **Agreement**.
14. The **IC** may terminate this **Agreement** if the **Licensee** is in default in the performance of any material obligation under this **Agreement**, and if the default has not been remedied within ninety (90) days after the date of written notice by the **IC** of the default.
15. Within thirty (30) days of the termination or expiration of this **Agreement**, the **Licensee** agrees to return all **Materials** and the **Licensed Products** to the **IC** or provide the **IC** with written certification of their destruction.
16. Within ninety (90) days of termination, expiration or term extension of this **Agreement**, the **Licensee** agrees to submit a report to the **IC**, and to submit to the **IC** payment of any royalties due.
    1. The report shall include, but not be limited to, progress on the research and development involving the **Materials** or the **Licensed Products** and use of the **Materials** or the **Licensed Products**. The **Licensee** shall send the report to the **IC** at the Mailing Address for **Agreement** notices indicated on the Signature Page or electronically mailed to the email address indicated on the Signature Page;
    2. If the term of the **Agreement** is extended at the **Licensee’s** request, then the **IC** and the **Licensee** will negotiate in good faith regarding the schedule for reports regarding the information required in 16(a);
    3. If the term of this **Agreement** is longer than ten (10) years, then the **IC** may request a status update report after the fifth (5th) year of the **Agreement**; and
    4. The **Licensee** may not be granted additional **IC** licenses if this reporting requirement is not fulfilled.
17. All plans and reports required by this **Agreement** shall be treated by the **IC** as commercial and financial information obtained from a person and as privileged and confidential and, to the extent permitted by law, not subject to disclosure under the Freedom of Information Act, [5 U.S.C. §552](http://frwebgate.access.gpo.gov/cgi-bin/usc.cgi?ACTION=RETRIEVE&FILE=$$xa$$busc5.wais&start=187300&SIZE=125455&TYPE=TEXT).
18. The **Licensee** is encouraged to publish the results of its research projects using the **Materials** or the **Licensed Products**. In all oral presentations or written publications concerning the **Materials** or the **Licensed Products**, the **Licensee** shall acknowledge the contribution of Dr. \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ and the **HHS** agency supplying the **Materials**, unless requested otherwise by the **IC** or Dr. \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_.
19. This **Agreement** shall be construed in accordance with U.S. Federal law, as interpreted and applied by the U.S. Federal courts in the District of Columbia. Federal law and regulations shall preempt any conflicting or inconsistent provisions in this **Agreement**. The **Licensee** agrees to be subject to the jurisdiction of U.S. courts.
20. This **Agreement** constitutes the entire understanding of the **IC** and the **Licensee** and supersedes all prior agreements and understandings with respect to the **Materials** or the **Licensed Products**.
21. The provisions of this **Agreement** are severable, and in the event that any provision of this **Agreement** shall be determined to be invalid or unenforceable under any controlling body of law, the invalidity or unenforceability of any provision of this **Agreement**, shall not in any way affect the validity or enforceability of the remaining provisions of this **Agreement**.
22. Paragraphs 10, 11, 15, 16, 17, 18 and 22 of this **Agreement** shall survive termination or expiration of this **Agreement**.
23. The terms and conditions of this **Agreement** shall, at the **IC’s** sole option, be considered by the **IC** to be withdrawnfrom the **Licensee’s** consideration and the terms and conditions of this **Agreement**,and the **Agreement** itself to be null and void,unless this **Agreement** is executedby the **Licensee** and a fully executed original is received by the **IC** within sixty (60) days from the date of the **IC** signature found at the Signature Page.

**SIGNATURES BEGIN ON NEXT PAGE**

**NIH BIOLOGICAL MATERIALS LICENSE AGREEMENT**

**FOR LICENSEE’S INTERNAL USE ONLY**

**SIGNATURE PAGE**

In Witness Whereof, the parties have executed this **Agreement** on the dates set forth below. Any communication or notice to be given shall be forwarded to the respective addresses listed below.

For the **IC**:

\_\_\_\_\_\_\_\_\_**DRAFT**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Name Date

Title

Office

National Institutes of Health

Address for Agreement notices and reports:

E-mail: [LicenseNotices\_Reports@mail.nih.gov](mailto:LicenseNotices_Reports@mail.nih.gov)(preferred)

Mail:      License Compliance and Administration

Monitoring & Enforcement

Office of Technology Transfer

National Institutes of Health

6701 Rockledge Drive, Suite 700, MS 7788

Bethesda, Maryland 20892 U.S.A.

(For courier deliveries please check <https://www.ott.nih.gov/licensing/license-noticesreports>)

For the **Licensee** (Upon, information and belief, the undersigned expressly certifies or affirms that the contents of any statements of the **Licensee** made or referred to in this document are truthful and accurate.):

by:

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ **DRAFT** \_\_\_\_\_\_\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_  
Signature of Authorized Official Date

Printed Name

Title

1. Official and Mailing Address for **Agreement** notices:

Name

Title

Mailing Address

Email Address:

Phone:

Fax:

1. Official and Mailing Address for Financial notices (The **Licensee’s** contact person for royalty payments)

Name

Title

Mailing Address

Email Address:

Phone:

Fax:

Any false or misleading statements made, presented, or submitted to the United States Government, including any relevant omissions, under this **Agreement** and during the course of negotiation of this **Agreement** are subject to all applicable civil and criminal statutes including Federal statutes [31 U.S.C. §§3801-3812](http://frwebgate.access.gpo.gov/cgi-bin/usc.cgi?ACTION=BROWSE&TITLE=31USCSIII&PDFS=YES) (civil liability) and [18 U.S.C. §1001](http://frwebgate.access.gpo.gov/cgi-bin/usc.cgi?ACTION=RETRIEVE&FILE=$$xa$$busc18.wais&start=1925859&SIZE=10370&TYPE=TEXT) (criminal liability including fine(s) and/or imprisonment).

APPENDIX A – SHIPPING INFORMATION

**The Licensee’s Shipping Contact: information or questions regarding shipping should be directed to the Licensee’s Shipping Contact at:**

Shipping Contact’s Name Title

Phone: () Fax: () E-mail:

**Shipping Address: Name & Address to which Materials should be shipped (please be specific):**

Company Name & Department

Address:

The **Licensee’s** shipping carrier and account number to be used for shipping purposes:

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Appendix B – Royalty Payment Options

New Payment Options Effective March 2018

**The License Number MUST appear on payments, reports and correspondence**.

**Credit and Debit Card Payments:** Credit and debit card payments can be submitted for amounts up to $24,999. Submit your payment through the U.S. Treasury web site located at: [**https://www.pay.gov/public/form/start/28680443**](https://www.pay.gov/public/form/start/28680443)**.**

**Automated Clearing House (ACH) for payments through U.S. banks only**

The **IC** encourages its licensees to submit electronic funds transfer payments through the Automated Clearing House (ACH). Submit your ACH payment through the U.S. Treasury web site located at: <https://www.pay.gov/public/form/start/28680443>. Please note that the IC "only" accepts ACH payments through this U.S. Treasury web site.

**Electronic Funds Wire Transfers:** The following account information is provided for wire payments. In order to process payment via Electronic Funds Wire Transfer sender MUST supply the following information within the transmission:

Drawn on a **U.S. bank account** via FEDWIRE:

Please provide the following instructions to your Financial Institution for the remittance of Fedwire payments to the **NIH ROYALTY FUND**.

| Fedwire Field Tag | Fedwire Field Name | Required Information |
| --- | --- | --- |
|  | | |
| {1510} | Type/Subtype | **1000** |
| {2000} | Amount | *(enter payment amount)* |
| {3400} | Receiver ABA routing number\* | **021030004** |
| {3400} | Receiver ABA short name | **TREAS NYC** |
| {3600} | Business Function Code | **CTR** (*or CTP*) |
| {4200} | Beneficiary Identifier (account number) | *(enter 12 digit gateway account #)*  **875080031006** |
| {4200} | Beneficiary Name | *(enter agency name associated with the Beneficiary Identifier)*  **DHHS / NIH (75080031)** |
| {5000} | Originator | *(enter the name of the originator of the payment)*  **COMPANY NAME** |
| {6000} | Originator to Beneficiary Information – Line 1 | *(enter information to identify the purpose of the payment)*  **ROYALTY** |
| {6000} | Originator to Beneficiary Information – Line 2 | *(enter information to identify the purpose of the payment)*  **LICENSE NUMBER** |
| {6000} | Originator to Beneficiary Information – Line 3 | *(enter information to identify the purpose of the payment)*  ***INVOICE NUMBER*** |
| {6000} | Originator to Beneficiary Information – Line 4 | *(enter information to identify the purpose of the payment)* |
| Notes:  \*The financial institution address for Treasury’s routing number is 33 Liberty Street, New York, NY 10045. | | |

**Agency Contacts**: Office of Technology Transfer (OTT) (301) 496-7057 [OTT-Royalties@mail.nih.gov](mailto:OTT-Royalties@mail.nih.gov)

Drawn on a **foreign bank account** via FEDWIRE:

The following instructions pertain to the Fedwire Network. Deposits made in US Dollars (USD).

Should your remitter utilize a correspondent US domestic bank in transferring electronic funds, the following Fedwire instructions are applicable.

| Fedwire Field Tag | Fedwire Field Name | Required Information |
| --- | --- | --- |
|  | | |
| {1510} | Type/Subtype | **1000** |
| {2000} | Amount | *(enter payment amount)* |
| {3100} | Sender Bank ABA routing number | *(enter the US correspondent bank’s ABA routing number)* |
| {3400} | Receiver ABA routing number\* | **021030004** |
| {3400} | Receiver ABA short name | **TREAS NYC** |
| {3600} | Business Function Code | **CTR** (*or CTP*) |
| {4200} | Beneficiary Identifier (account number)\*\* | *(enter 12 digit gateway account #)*  **875080031006** |
| {4200} | Beneficiary Name | *(enter agency name associated with the Beneficiary Identifier)*  **DHHS / NIH (75080031)** |
| {5000} | Originator | *(enter the name of the originator of the payment)*  **COMPANY’S NAME** |
| {6000} | Originator to Beneficiary Information – Line 1 | *(enter information to identify the purpose of the payment)*  **ROYALTY** |
| {6000} | Originator to Beneficiary Information – Line 2 | *(enter information to identify the purpose of the payment)*  **LICENSE NUMBER** |
| {6000} | Originator to Beneficiary Information – Line 3 | *(enter information to identify the purpose of the payment)*  ***INVOICE NUMBER*** |
| {6000} | Originator to Beneficiary Information – Line 4 | *(enter information to identify the purpose of the payment)* |
| Notes:   \*The financial institution address for Treasury’s routing number is 33 Liberty Street, New York, NY 10045.  \*\*Anything other than the 12 digit gateway account # will cause the Fedwire to be returned – **SWIFT CODE: FRNYUS33** | | |

**Agency Contacts**:

Office of Technology Transfer (OTT) (301) 496-7057 [OTT-Royalties@mail.nih.gov](mailto:OTT-Royalties@mail.nih.gov)

**Checks**

All checks should be made payable to “NIH Patent Licensing”

Checks drawn on a **U.S. bank account** and sent by US Postal Service should be sent directly to the following address:

National Institutes of Health

P.O. Box 979071

St. Louis, MO 63197-9000

Checks drawn on a U.S. bank account and sent by **overnight or courier** should be sent to the following address:

US Bank

Government Lockbox SL-MO-C2GL

3180 Rider Trail S.

Earth City, MO 63045

Phone: (800) 495-4981

Checks drawn on a **foreign bank account** should be sent directly to the following address:

National Institutes of Health

Office of Technology Transfer

License Compliance and Administration

Royalty Administration

6701 Rockledge Drive

Suite 700, MSC 7788

Bethesda, Maryland 20892